BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18615122)

  • 21. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients.
    Loutfy MR; Raboud JM; Antoniou T; Kovacs C; Shen S; Halpenny R; Ellenor D; Ezekiel D; Zhao A; Beninger F
    AIDS; 2007 May; 21(9):1147-55. PubMed ID: 17502725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Facial fat volume in HIV-infected patients with lipoatrophy.
    Yang Y; Sitoh YY; Oo Tha N; Paton NI
    Antivir Ther; 2005; 10(4):575-81. PubMed ID: 16038484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone.
    Orentreich D; Leone AS
    Dermatol Surg; 2004 Apr; 30(4 Pt 1):548-51. PubMed ID: 15056149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy.
    Ramon Y; Fodor L; Ullmann Y
    Dermatology; 2007; 214(2):151-4. PubMed ID: 17341865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plastic surgical approaches for HIV-associated lipoatrophy.
    Moyle GJ
    Curr HIV/AIDS Rep; 2005 Aug; 2(3):127-31. PubMed ID: 16091259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment strategies for HIV lipodystrophy.
    Carr A
    Curr Opin HIV AIDS; 2007 Jul; 2(4):332-8. PubMed ID: 19372908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy.
    Bechara FG; Gambichler T; Brockmeyer NH; Sand M; Altmeyer P; Hoffmann K
    Dermatology; 2008; 217(3):244-9. PubMed ID: 18663308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients as measured by four quality-of-life questionnaires.
    Warde M; Gragnani A; Gomes H; Hochman B; Ferreira LM
    Int J STD AIDS; 2011 Oct; 22(10):596-9. PubMed ID: 21998182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of facial lipoatrophy by lipofilling in HIV infected patients: retrospective study on 317 patients on 9 years].
    Uzzan C; Boccara D; Lacheré A; Mimoun M; Chaouat M
    Ann Chir Plast Esthet; 2012 Jun; 57(3):210-6. PubMed ID: 22218365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term complications of antiretroviral therapy: lipoatrophy.
    Waters L; Nelson M
    Int J Clin Pract; 2007 Jun; 61(6):999-1014. PubMed ID: 17504362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-slice computed tomography and anthropometric skinfold analysis for evaluation of facial lipoatrophy in HIV-infected patients.
    Padilla S; Gallego JA; Masiá M; Gutiérrez F
    Clin Infect Dis; 2004 Dec; 39(12):1848-51. PubMed ID: 15578410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients.
    Pavicic T; Ruzicka T; Korting HC; Gauglitz G
    J Drugs Dermatol; 2010 Jun; 9(6):690-5. PubMed ID: 20645533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current perspectives on HIV-associated lipodystrophy syndrome.
    Milinkovic A; Martinez E
    J Antimicrob Chemother; 2005 Jul; 56(1):6-9. PubMed ID: 15905302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial.
    Jones DH; Carruthers A; Orentreich D; Brody HJ; Lai MY; Azen S; Van Dyke GS
    Dermatol Surg; 2004 Oct; 30(10):1279-86. PubMed ID: 15458523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients.
    Mansor S; Breiting VB; Dahlstrøm K; Andersen AB; Andersen O; Christensen LH
    Aesthetic Plast Surg; 2011 Oct; 35(5):709-16. PubMed ID: 21359981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Facial lipoatrophy: appearances are not deceiving.
    Sanches RS; Mill J; Machado AA; Donadi EA; Morais Fernandes AP
    J Assoc Nurses AIDS Care; 2009; 20(3):169-75. PubMed ID: 19427594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-density hyaluronic acid for the treatment of HIV-related facial lipoatrophy.
    Pignatti M; Pedone A; Baccarani A; Guaraldi G; Orlando G; Lombardi M; De Santis G
    Aesthetic Plast Surg; 2012 Feb; 36(1):180-5. PubMed ID: 21717261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-associated lipodystrophy syndrome.
    Milinković A
    Coll Antropol; 2006 Dec; 30 Suppl 2():59-62. PubMed ID: 17508476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical management of HIV-associated lipodystrophy.
    Pirmohamed M
    Curr Opin Lipidol; 2009 Aug; 20(4):309-14. PubMed ID: 19494771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
    Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
    Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.